Ampliphi Biosciences Corp (APHB)

1.50
0.03 1.96
AMEX : Health Care
Prev Close 1.53
Open 1.50
Day Low/High 1.46 / 1.60
52 Wk Low/High 1.45 / 13.50
Volume 80.38K
Avg Volume 175.90K
Exchange AMEX
Shares Outstanding 8.24M
Market Cap 13.02M
EPS -33.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

AmpliPhi Biosciences To Be Granted European Patent Covering The Use Of Phage Therapy To Resensitize Bacterial Infections To Antibiotics

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that the European Patent Office has...

AmpliPhi Biosciences Announces Pricing Of Registered Direct Public Offering Of Common Stock And Warrants

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the pricing of a registered direct...

AmpliPhi Biosciences' CEO To Discuss Novel Approaches To Fighting Drug-Resistant Pathogens In Panel At BIO International

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M.

AmpliPhi Biosciences Announces Start Of First Phage Therapy Trial In U.S. Under IND

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has dosed the first patient in its...

AmpliPhi Biosciences Reports First Quarter 2016 Financial Results And Provides Corporate Update

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first...

AmpliPhi Biosciences To Host Conference Call And Webcast Discussion Of First Quarter 2016 Financial Results On May 13, 2016

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results...

AmpliPhi Biosciences Provides Update On Phase I Trial: Phage Therapy Well Tolerated In First Cohort

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing...

AmpliPhi Biosciences Terminates Collaboration Agreement With Intrexon

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to...

AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical...

AmpliPhi Biosciences Announces Conversion Of All Series B Redeemable Preferred Stock Into Common Stock

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that all 7.

AmpliPhi Biosciences Reports Full-Year 2015 Financial Results

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the fiscal year ended...

AmpliPhi Biosciences To Host Full-Year 2015 Financial Results Conference Call And Webcast On March 30, 2016

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the...

AmpliPhi Biosciences CEO To Present At 28th Annual ROTH Conference

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M.

AmpliPhi Biosciences Announces Award Of Federal Research Grant From Australia To Its Collaboration Partner, Westmead Institute

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, congratulates the Westmead Institute's Centre for Infectious...

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

AmpliPhi Biosciences Announces Dosing Of First Patient In Phase 1 Clinical Trial Of AB-SA01

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1...

AmpliPhi Biosciences Announces Appointment Of Steve R. Martin As Chief Financial Officer

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Steve R.

AmpliPhi Acquires Key Bacteriophage Assets From UK-based Novolytics

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has acquired key assets from UK-based...

AmpliPhi Signs Clinical Trial Agreement With University Of Adelaide To Conduct A Phase I Trial Of Bacteriophage Therapy For Treating Staphylococcus Aureus Infections

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical...

AmpliPhi Announces Board Expansion With Appointment Of Two Highly-Experienced Non-Executive Directors

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Vijay B.

AmpliPhi's Chief Executive Officer, M. Scott Salka, Gives Interview To The Wall Street Transcript

M. Scott Salka, the Chief Executive Officer of AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the discovery, development and commercialization of novel bacteriophage therapeutics,...

AmpliPhi Announces Data Demonstrating Efficacy Of A Novel Bacteriophage Cocktail Is Comparable To Vancomycin In S. Aureus Lung Infection Model

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced experimental results highlighting that...

AmpliPhi Biosciences To Present At Rodman & Renshaw 17th Annual Global Investment Conference

AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M.

AmpliPhi Biosciences Announces Appointment Of Alexander Gaidamaka As Vice President Of Chemistry, Manufacturing And Control

AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Alexander Gaidamaka, Ph.

AmpliPhi To Present At The 21st Biennial Evergreen International Phage Meeting

AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today...

AmpliPhi BioSciences Cleared To Submit Listing Application To NYSE MKT

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a...

AmpliPhi To Present Research On Efficacy Of A Novel Bacteriophage Cocktail In S. Aureus Lung Infection Model At ICAAC/ICC 2015

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that data comparing the efficacy of its...

AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that...

AmpliPhi To Present New Data On Biological Activity Of Nebulized Anti-Pseudomonal Bacteriophage

AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P.

AmpliPhi's Bacteriophage Manufacturing Facility Receives CGMP Certification

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana,...